Bicara Therapeutics (NASDAQ:BCAX) Coverage Initiated by Analysts at Wedbush

Stock analysts at Wedbush began coverage on shares of Bicara Therapeutics (NASDAQ:BCAX) in a note issued to investors on Thursday,Briefing.com Automated Import reports. The brokerage set an “outperform” rating and a $31.00 price target on the stock. Wedbush’s price target points to a potential upside of 143.71% from the stock’s previous close.

A number of other equities analysts have also issued reports on the stock. Rodman & Renshaw initiated coverage on shares of Bicara Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 target price for the company. RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. Finally, HC Wainwright increased their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $41.20.

Bicara Therapeutics Price Performance

Bicara Therapeutics stock opened at $12.72 on Thursday. The business’s 50-day moving average price is $16.00. Bicara Therapeutics has a one year low of $11.10 and a one year high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). Equities research analysts predict that Bicara Therapeutics will post -2.59 EPS for the current year.

Institutional Trading of Bicara Therapeutics

A number of hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. purchased a new stake in Bicara Therapeutics during the third quarter valued at about $177,169,000. FMR LLC purchased a new stake in Bicara Therapeutics during the third quarter valued at about $57,913,000. Braidwell LP purchased a new stake in Bicara Therapeutics during the third quarter valued at about $42,219,000. Janus Henderson Group PLC purchased a new stake in Bicara Therapeutics during the third quarter valued at about $30,329,000. Finally, Baker BROS. Advisors LP purchased a new stake in Bicara Therapeutics during the third quarter valued at about $21,225,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.